



November 14, 2014

**OFFICERS**

The Hon. John Edward Porter, Chair  
The Hon. Michael N. Castle, Vice Chair  
Mary Woolley, President  
Larry J. Shapiro, MD, Secretary  
Lucinda Maine, PhD, RPh, Treasurer

**BOARD MEMBERS**

Tenley E. Albright, MD  
Hortensia Amaro, PhD  
Georges C. Benjamin, MD  
Nancy Brown  
Susan Dentzer  
Victor J. Dzau, MD  
Joseph M. Fecko, MD  
Jay A. Gershen, DDS, PhD  
William N. Hait, MD, PhD  
Larry Hausner, MBA  
Mary J.C. Hendrix, PhD  
Martha N. Hill, PhD, RN  
Harry Johns  
Evan Jones  
Elizabeth Baker Keffer  
The Hon. Patrick J. Kennedy  
Debra R. Lappin, JD  
Alan I. Leshner, PhD  
James L. Madara, MD  
Mark McClellan, MD, PhD  
The Hon. Kweisi Mfume  
Herbert Pardes, MD  
Sudip S. Parikh, PhD  
E. Albert Reece, MD, PhD, MBA  
Amy Comstock Rick, JD  
John R. Seffrin, PhD  
Laing Rogers Sisto  
Gregory Sorensen, MD  
Jack T. Watters, MD  
Keith R. Yamamoto, PhD  
Elias A. Zerhouni, MD

The Honorable Fred Upton  
Chairman  
Committee on Energy and Commerce  
2322A Rayburn House Office Building  
Washington, D.C. 20515

The Honorable Diana DeGette  
Ranking Member  
Subcommittee on Oversight and Investigations  
Committee on Energy and Commerce  
2368 Rayburn House Office Building  
Washington, DC 20515

Dear Chairman Upton and Ranking Member DeGette,

I am writing on behalf of Research!America, the nation's largest advocacy and public education alliance committed to elevating the priority of U.S. medical progress. We truly appreciate your dedicated efforts and the thorough, consultative process you are employing under the 21st Century Cures initiative to identify and clear roadblocks to medical innovation. There is no doubt that the time and work you and your staff are investing in this initiative will provide a meaningful return to patients in the US and throughout the world.

We understand that you plan to introduce 21st Century Cures legislation translating your findings into concrete action, and hope you will consider including Congressman Buschon's Research and Development Efficiency Act (H.R. 5056) in that legislation.


H.R. 5056 is a straightforward measure that charges the White House Office of Science and Technology Policy (OSTP) with establishing a public process to streamline the onerous administrative requirements surrounding federally funded research. Over-regulation is always deleterious, but when it siphons federal dollars from finding new treatments and cures and buries promising medical research in mounds of red tape, patients and taxpayers both pay the price. Efficiencies that reduce the resources and time required to meet research-related regulatory requirements can literally save lives. It is that important.

While H.R. 5056 passed the House by unanimous consent, it is unlikely the Senate will have time to consider the legislation before the 113th Congress adjourns.

Research!America believes H.R. 5056 is emblematic of the common-sense actions you have so faithfully pursued as you seek to end unjustifiable delays in life-saving medical progress.

Thank you for considering our views, and we'd also like to thank Clay Alspach and the other members of the 21st century team for their terrific work throughout this process. Please do not hesitate to contact me if I can provide additional information.

Sincerely,

  
Mary Woolley  
President and CEO

1101 King Street  
Suite 520  
Alexandria, VA 22314-2960  
P 703.739.2577  
F 703.739.2372  
E [info@researchamerica.org](mailto:info@researchamerica.org)  
[www.researchamerica.org](http://www.researchamerica.org)